pour la recherche uniquement
Réf. Catalogue: S1949
Structure chimique
| Lignées cellulaires | Type d'essai | Concentration | Temps d'incubation | Formulation | Description de l'activité | PMID |
|---|---|---|---|---|---|---|
| HT22 cells | Function assay | Neuroprotective activity in mouse HT22 cells assessed as prevention from glutamate-induced oxidative cell death by MTS assay, PD50=0.797 μM | ||||
| HeLa cell | Cytotoxicity assay | Cytotoxicity against HeLa cell lines, EC50=3.7 μM | ||||
| PaCa2 cell | Proliferation assay | Antiproliferative activity against human pancreatic carcinoma Mia PaCa2 cell line by colorimetric assay, IC50=6.2 μM | ||||
| HT-29 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=9.69 μM | |||
| DU145 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=9.86 μM | |||
| MDA-MB-231 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=12.68 μM | |||
| human A2058 cells | Cytotoxicity assay | Cytotoxicity against human A2058 cells assessed as inhibition of formazan formation at day 5 by measuring absorbance at 430 nm, IC50=13.4 μM | ||||
| SAS cells | Cytotoxicity assay | 48 h | Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50=14 μM | |||
| HaCaT cells | Function assay | 48 h | Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy, IC50=15.8 μM | |||
| HeLa cells | Cytotoxicity assay | 48 h | Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50=18 μM | |||
| CRL2796 cells | Cytotoxicity assay | Cytotoxicity against human CRL2796 cells assessed as inhibition of formazan formation at day 4 by measuring absorbance at 430 nm, IC50=21 μM | ||||
| HL60 cells | Function assay | 50 μM | Induction of necrosis in intact human HL60 cells assessed as cytosolic LDH release at 50 uM | |||
| Cliquez pour voir plus de données expérimentales sur la lignée cellulaire | ||||||
| Poids moléculaire | 172.18 | Formule | C11H8O2 |
Stockage (À compter de la date de réception) | 3 years-20°C(in the dark) powder |
|---|---|---|---|---|---|
| N° CAS | 58-27-5 | Télécharger le SDF | Stockage des solutions mères |
|
|
| Synonymes | NSC 4170 | Smiles | CC1=CC(=O)C2=CC=CC=C2C1=O | ||
|
In vitro |
DMSO
: 34 mg/mL
(197.46 mM)
Ethanol : 34 mg/mL Water : Insoluble |
|
In vivo |
|||||
Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant l'expérience)
Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter d'abord s'il n'y a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter d'abord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.
Note : 1. Veuillez vous assurer que le liquide est clair avant d'ajouter le solvant suivant.
2. Assurez-vous d'ajouter le(s) solvant(s) dans l'ordre. Vous devez vous assurer que la solution obtenue, lors de l'ajout précédent, est une solution claire avant de procéder à l'ajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.
| Targets/IC50/Ki |
Cdc25 phosphatase
DNA polymerase γ
|
|---|---|
| In vitro |
Menadione (Vitamin K3) prevents mitochondrial Ca(2+) uptake in normal pancreatic acinar cells, which permits rapid spread of Ca(2+) throughout the cell. Its-induced mitochondrial depolarisation is due to induction of the permeability transition pore. At nontoxic concentration, this compound results in a brief activation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in the RALA255-10G rat hepatocyte cell line. It is equipotent against multidrug-resistant and parental leukemia cell lines with IC50 values of 13.5 mM and 18 mM, respectively. The compound inhibits the incorporation of radioactive thymidine, uridine and amino acids into DNA, RNA and protein, respectively, in three humancancer cell lines. At 1-20 mM, it dose- and time-dependently inhibits cell proliferation of AR4-2J cells. A concentration of 100 mM causes rapid cell death. This level (100 mM) induces DNA smear in electrophoresis indicative of necrosis, while lower concentrations (10-20 mM) induces a DNA ladder indicative of apoptosis. Concentrations of 1-20 mM induce wild-type P53, whereas 100 mM has a minor effect on wild-type P53. Treatment with it clearly affects the mitochondrial function of Jurkat T cells by inducing a collapse of the inner transmembrane potential (DeltaPsi(m)) and a decrease in inner membrane mass, which could be completely reversed by N-acetylcysteine. |
Références |
|
| Méthodes | Biomarqueurs | Images | PMID |
|---|---|---|---|
| Western blot | p-JNK / JNK / p-c-Jun / c-Jun / p-ERK / ERK Cyclin B1 / CDK1 / CDC25C c-Fos / HO-1 |
|
20578144 |
(données du https://clinicaltrials.gov, mis à jour le 2024-05-22)
| Numéro NCT | Recrutement | Conditions | Promoteur/Collaborateurs | Date de début | Phases |
|---|---|---|---|---|---|
| NCT01094444 | Completed | Folliculitis |
Per Pfeiffer|Odense University Hospital |
May 2010 | Phase 2 |
| NCT00656786 | Completed | EGFR Inhibitor-associated Rash |
Spectrum Pharmaceuticals Inc |
April 3 2008 | Phase 1 |